https://www.selleckchem.com/products/odm-201.html
Background Novel oral anticoagulants (NOACs) were developed as alternatives to warfarin. However, the patients' preference regarding warfarin or the NOACs has not been established. Quality-of-life (QOL) surveys are a well-established method for determining the patients' preference for a treatment route. Aims This study compared the patients' perspectives on treatment with warfarin versus apixaban using the QOL measures. Settings and design This cross-sectional study was conducted in 2019 for patients treated with either warfarin or apix
Like
Comment
Share
